Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Alanine Transaminase

Alanine Transaminase

Alanine transaminase (ALT) is a crucial enzyme found in the liver and other tissues, playing a vital role in amino acid metabolism.
It catalyzes the reversible transfer of an amino group from alanine to α-ketoglutarate, producing pyruvate and glutamate.
Elevated ALT levels can indicate liver injury or disease, making it an important biomarker for monitoring and diagnosing conditions like hepatitis, cirrhosis, and non-alcoholic fatty liver disease.
Accurate and reproducible ALT analysis is essential for clinical decision-making and research.
PubCompare.ai's AI-driven protocols can enhance the reproducibility and accuracy of ALT analysis by leveraging intelligent comparisons to identify the best protocols and products from literature, pre-prints, and patents.
Optimize your ALT research with PubCompare.ai's seamless integration of scientific data.

Most cited protocols related to «Alanine Transaminase»

1
Dionysos Nutrition and Liver Study
Cited 176 times
The protocol of the Dionysos Nutrition & Liver Study was described in detail elsewhere [1 (link)]. Briefly, of 5780 residents of Campogalliano (Modena, Italy) aged 18 to 75 years, 3345 (58%) agreed to participate to the study; 3329 (99%) of them had all the data required by the Dionysos Project [7 (link),13 (link)] and were considered for further analysis. 497 (15%) of them had suspected liver disease (SLD) according to at least one of the following criteria: 1) alanine transaminase (ALT) > 30 U*L-1; 2) gamma-glutamyl-transferase (GGT) > 35 U*L-1; 3) presence of hepatitis B surface antigen (HBsAg); 4) presence of Hepatitis C (HCV) virus ribonucleic acid (RNA) after detection of anti-HCV antibodies. The 497 subjects with SLD were matched with an equal number of subjects of the same age and sex but without SLD, randomly selected among the remaining 2832 subjects. After exclusion of subjects with HBV or HCV infection, the original analysis was performed on 224 subjects with and 287 without SLD [1 (link)]. The present analysis is performed on 216 (96%) subjects with and 280 (97%) without SLD, based on the availability of skinfold measurements.
Bedogni G., Bellentani S., Miglioli L., Masutti F., Passalacqua M., Castiglione A, & Tiribelli C. (2006). The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology, 6, 33.
Full text: Click here
Publication 2006
Alanine Transaminase gamma-Glutamyl Transpeptidase Hepatitis B Surface Antigens Hepatitis C Hepatitis C Antibodies Liver Diseases Liver Function Tests RNA Virus
2
Diagnostic Approach for Hypersensitivity Pneumonitis
Cited 53 times
A multidisciplinary (pulmonologists, radiologists, methodologists, pathologists, and patient) panel of experts from the ATS, JRS, and ALAT was composed to identify clinically important questions about diagnostic testing for HP among patients with newly identified ILD. The CPG was created in two parts. The first portion describes clinical, radiological, and pathological features of HP while proposing a definition, diagnostic criteria, and a diagnostic algorithm. It was approached in a consensus fashion and informed by a nonsystematic review of the literature. The second portion makes graded recommendations that answer questions about whether to perform a diagnostic intervention. It was informed by National Academy of Medicine–adherent guideline methodology, including a full systematic review for each question and the formulation, writing, and grading of recommendations using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. For a detailed description of the methods, see the online supplement.
Implications of the different degrees of recommendation are described in Table 1. Using the GRADE approach, each recommendation was rated as either a “recommendation” or a “suggestion.” The meaning of a recommendation is the same as a strong recommendation in typical GRADE nomenclature, and the meaning of a suggestion is the same as a weak or conditional recommendation in typical GRADE nomenclature. Typical GRADE nomenclature was altered for this guideline to address prior criticism that the term “conditional” created uncertainty in the context of translation into non-English languages.
Raghu G., Remy-Jardin M., Ryerson C.J., Myers J.L., Kreuter M., Vasakova M., Bargagli E., Chung J.H., Collins B.F., Bendstrup E., Chami H.A., Chua A.T., Corte T.J., Dalphin J.C., Danoff S.K., Diaz-Mendoza J., Duggal A., Egashira R., Ewing T., Gulati M., Inoue Y., Jenkins A.R., Johannson K.A., Johkoh T., Tamae-Kakazu M., Kitaichi M., Knight S.L., Koschel D., Lederer D.J., Mageto Y., Maier L.A., Matiz C., Morell F., Nicholson A.G., Patolia S., Pereira C.A., Renzoni E.A., Salisbury M.L., Selman M., Walsh S.L, & Wuyts W.A. (2020). Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 202(3), e36-e69.
Publication 2020
Alanine Transaminase Debility Diagnosis Dietary Supplements Pathologists Patients Pulmonologists Radiologist X-Rays, Diagnostic
3
Serum Biomarkers for NAFLD Diagnosis
Cited 28 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2019
Alanine Transaminase Aspartate Transaminase Blood Platelets Cytokeratin 18 Diet, Formula Fatty Liver Fibrosis Fibrosis, Liver Hepatitis C virus Liver Non-alcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis Patients Precursor, Complement C3 procollagen Type III-N-terminal peptide Steatohepatitis
4
Compassionate Use of Remdesivir for COVID-19
Cited 19 times
Gilead Sciences began accepting requests from clinicians for compassionate use of remdesivir on January 25, 2020. To submit a request, clinicians completed an assessment form with demographic and disease-status information about their patient (see the Supplementary Appendix, available with the full text of this article at NEJM.org). Approval of requests was reserved for hospitalized patients who had SARS-CoV-2 infection confirmed by reverse-transcriptase–polymerase-chain-reaction assay and either an oxygen saturation of 94% or less while the patient was breathing ambient air or a need for oxygen support. In addition, patients were required to have a creatinine clearance above 30 ml per minute and serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than five times the upper limit of the normal range, and they had to agree not to use other investigational agents for Covid-19.
In approved cases, the planned treatment was a 10-day course of remdesivir, consisting of a loading dose of 200 mg intravenously on day 1, plus 100 mg daily for the following 9 days. Supportive therapy was to be provided at the discretion of the clinicians. Follow-up was to continue through at least 28 days after the beginning of treatment with remdesivir or until discharge or death. Data that were collected through March 30, 2020, are reported here. This open-label program did not have a predetermined number of patients, number of sites, or duration. Data for some patients included in this analysis have been reported previously.20-22 Details of the study design and conduct can be seen in the protocol (available at NEJM.org).
Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A., Feldt T., Green G., Green M.L., Lescure F.X., Nicastri E., Oda R., Yo K., Quiros-Roldan E., Studemeister A., Redinski J., Ahmed S., Bernett J., Chelliah D., Chen D., Chihara S., Cohen S.H., Cunningham J., D’Arminio Monforte A., Ismail S., Kato H., Lapadula G., L’Her E., Maeno T., Majumder S., Massari M., Mora-Rillo M., Mutoh Y., Nguyen D., Verweij E., Zoufaly A., Osinusi A.O., DeZure A., Zhao Y., Zhong L., Chokkalingam A., Elboudwarej E., Telep L., Timbs L., Henne I., Sellers S., Cao H., Tan S.K., Winterbourne L., Desai P., Mera R., Gaggar A., Myers R.P., Brainard D.M., Childs R, & Flanigan T. (2020). Compassionate Use of Remdesivir for Patients with Severe Covid-19. The New England Journal of Medicine.
Publication 2020
Aftercare Alanine Transaminase Aspartate Transaminase Biological Assay Compassionate Use COVID 19 Creatinine Oxygen Oxygen Saturation Patient Discharge Patients remdesivir Reverse Transcriptase Polymerase Chain Reaction Serum Therapeutics Vision
5
Comprehensive metabolic and lifestyle assessment
Cited 19 times
We measured physical activity (mins /day of at least moderate intensity, mins /day of sedentary time, steps per day and total accelerometer counts) using Actigraph GT3XE accelerometers. We measured resting systolic and diastolic blood pressure (taking the lowest of three measurements in the right arm, following at least 3 minutes seated); fasting plasma glucose; fasting LDL, HDL and total cholesterol; triglycerides; glycosylated haemoglobin (HbA1c); liver function tests (our clinical liaison specified alanine transaminase (ALT), which is used as a marker of inflammation [33 (link)] as the main variable of interest); BMI; waist circumference (mean of three consecutive measurements); dietary intake (using the DINE questionnaire) [34 (link)]; and the EQ-5D health-related quality of life measure [35 (link)]. Based on clinical risk markers we calculated QRISK2 ten-year cardiovascular risk score [15 (link)] and the presence of metabolic syndrome (a composite cardiovascular risk classification based on having a combination of high waist circumference, fasting plasma glucose, blood pressure and /or lipid abnormalities. We used the WHO definition of metabolic syndrome to assess this [36 (link)]).
All outcomes were measured on entry into the study and 12 months later. Four months after baseline we assessed weight, physical activity and questionnaire-based measures to identify the immediate (short-term) impact of the intervention on weight and lifestyle behaviours.
Greaves C., Gillison F., Stathi A., Bennett P., Reddy P., Dunbar J., Perry R., Messom D., Chandler R., Francis M., Davis M., Green C., Evans P, & Taylor G. (2015). Waste the waist: a pilot randomised controlled trial of a primary care based intervention to support lifestyle change in people with high cardiovascular risk. The International Journal of Behavioral Nutrition and Physical Activity, 12, 1.
Full text: Click here
Publication 2015
Actigraphy Alanine Transaminase Blood Pressure Cholesterol Congenital Abnormality Glucose Hemoglobin, Glycosylated Inflammation Lipids Liver Function Tests Metabolic Syndrome X Plasma Pressure, Diastolic Systole Triglycerides Waist Circumference

Most recents protocols related to «Alanine Transaminase»

1
Cardiometabolic Risk Factors in NHANES
The following covariates were considered in the study: age, sex, race/ethnicity, family poverty income ratio (PIR), education level, marital status, the complication of hypertension, and diabetes mellitus (DM), smoker, drinker, body mass index (BMI), waist circumference, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean energy intake, hemoglobin (Hb), fast glucose (FBG), glycosylated hemoglobin (HbA1c), alanine transaminase (Alt), aspartate aminotransferase (Ast), albumin, total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), uric acid (UA), blood urea nitrogen (BUN), serum creatinine (Scr), and estimated glomerular filtration rate (eGFR). Individuals who have smoked less than 100 cigarettes in their lifetime/smoked less than 100 cigarettes in their lifetime, do not smoke at all at present/smoked more than 100 cigarettes in their lifetime, and smoke some days or every day were defined as never smoke, former smokers, and now smokers, respectively. There are three categories of drinkers: current heavy alcohol consumption were defined as ≥3 drinks per day for females, ≥4 drinks per day for males, or binge drinking [≥4 drinks on same occasion for females, ≥5 drinks on same occasion for males] on 5 or more days per month; current moderate alcohol consumption were defined as ≥2 drinks per day for females, ≥3 drinks per day for males, or binge drinking ≥2 days per month. Those who did not meet the above criteria were classified as current mild alcohol user.21 (link) Hypertension was defined as an average systolic blood pressure more than 140 mmHg/diastolic blood pressure greater than 90 mmHg or self-reported use of antihypertensive medication. DM will be assessed by measures of blood glycohemoglobin, fasting plasma glucose, 2-hour glucose (Oral Glucose Tolerance Test), serum insulin in participants aged 12 years and over. Hb, FBG, HbA1c, Alt, Ast, albumin, TC, TG, HDL-C, UA, BUN, Scr, and eGFR were all determined in the laboratory. More information regarding the variables used is available at https://www.cdc.gov/nchs/nhanes/index.htm.
Xiao S., Wang Z., Zuo R., Zhou Y., Yang Y., Chen T, & Liu N. (2023). Association of Systemic Immune Inflammation Index with All-Cause, Cardiovascular Disease, and Cancer-Related Mortality in Patients with Cardiovascular Disease: A Cross-Sectional Study. Journal of Inflammation Research, 16, 941-961.
Publication 2023
Alanine Transaminase Albumins Alcohols Antihypertensive Agents BLOOD Cholesterol Creatinine Diabetes Mellitus Ethnicity Females Glomerular Filtration Rate Glucose Hemoglobin Hemoglobin, Glycosylated High Blood Pressures High Density Lipoprotein Cholesterol Index, Body Mass Insulin Males Oral Glucose Tolerance Test Plasma Pressure, Diastolic Serum Smoke Systolic Pressure Transaminase, Serum Glutamic-Oxaloacetic Triglycerides Urea Nitrogen, Blood Uric Acid Waist Circumference
2
Comprehensive Health Evaluation of Postmenopausal Women
A structured and detailed survey designed by professional physicians was used to collect the demographic and clinical parameters of the study subjects including self-reported illness and the currently used medications. The number of subjects in the smoking and alcohol consumption groups were low among early postmenopausal women, and were therefore excluded from analysis. Systolic and diastolic blood pressure was measured using an electronic brachial sphygmomanometer (T30J, OMRON, Japan). Anthropometric parameters including height, weight, waist circumference, and hip circumference were measured using standard procedures by well-trained nurses. Blood samples (8–10 mL) were collected from the antecubital vein after at least 8 h of overnight fasting and evaluated in the laboratory center within 24 h. Metabolic biomarkers and liver function parameters including fasting blood glucose (FBG), triglycerides (TGs), total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), serum uric acid (UA), serum aspartate aminotransferase (AST), and serum alanine aminotransferase (ALT) levels were measured. Furthermore, the blood counts of white blood cells (WBC) and neutrophils (NE) were also analyzed. Abdominal ultrasonography was performed using the SIEMENS ACUSON S2000 ABVS ultrasound scanner (Siemens Healthineers, Erlangen, Germany), and was operated by experienced ultra-sonographers. The data was recorded in the electronic medical system of the Health Examination Center.
Lu Y., Ge L., Yang H., He Y, & Wang Y. (2023). Chinese Visceral Adipose Index Shows Superior Diagnostic Performance in Predicting the Risk of Metabolic Dysfunction Associated Fatty Liver Disease in Early Postmenopausal Chinese Women. Diabetes, Metabolic Syndrome and Obesity, 16, 607-617.
Publication 2023
Abdomen Alanine Transaminase Aspartate Transaminase Biological Markers BLOOD Blood Glucose Cholesterol Cholesterol, beta-Lipoprotein High Density Lipoprotein Cholesterol Leukocytes Liver Neutrophil Nurses Pharmaceutical Preparations Physicians Pressure, Diastolic Serum Sphygmomanometers Systole Triglycerides Ultrasonography Uric Acid Veins Waist Circumference Woman
3
Tumor Factors and Treatment Response
The following data were collected: demographic information (age, sex, body mass index; clinical history (hepatitis B or C virus carriers, alcohol consumption, diabetes, hypertension, cardiovascular disease, pulmonary disease, chronic kidney disease, Child–Pugh class, and BCLC staging); laboratory data (levels of aspartate transaminase, alanine transaminase, total bilirubin, albumin, platelet count, and serum alpha-fetoprotein); tumor factors (size and number of tumors); and imaging response within 1 month after the initial TACE. The up-to-seven criteria were calculated by the summation of the largest tumor diameter in cm and the number of tumors. Two strata of the scores included the summation of scores ≤ 7 or > 718 (link). The clinical and laboratory information were collected from the electronic medical records.
Bannangkoon K., Hongsakul K., Tubtawee T., Ina N, & Chichareon P. (2023). Association of myosteatosis with treatment response and survival in patients with hepatocellular carcinoma undergoing chemoembolization: a retrospective cohort study. Scientific Reports, 13, 3978.
Full text: Click here
Publication 2023
ADAM17 protein, human Alanine Transaminase Albumins alpha-Fetoproteins Bilirubin Cardiovascular Diseases Child Chronic Kidney Diseases Diabetes Mellitus Hepatitis B High Blood Pressures Index, Body Mass Lung Diseases Neoplasms Platelet Counts, Blood Serum Transaminase, Serum Glutamic-Oxaloacetic Virus
4
Switching from Premixed to Basal-Plus Insulin
The subjects were enrolled form the outpatient department of Tri-Service General Hospital between January 2018 and October 2019. All study subjects were anonymous, and informed consent was obtained prior to participation. The study proposal was reviewed and approved by the institutional review board of Tri-Service General Hospital
It is a single-arm, open, observational study. The subjects with documented T2D diagnosis longer than 3 months with aged from 40 to 80 with HbA1C levels between 7.0% to 11.0% under treatment of premixed insulin, NovoMix® 30 (30% insulin aspart and 70% insulin aspart protamine) with or without combination with metformin were enrolled into the study. The patients with Alanine transaminase (ALT) and Aspartate transaminase (AST) > 3 times normal, and estimated GFR < 30mL/minute/1.73m2, or major systemic disease were excluded from the study.
After enrollment, patients were scheduled for laboratory tests and insertion of CGMS after an 8 to 10 hours NPO. Patients were kept treating with premixed insulin for another week during CGMS insertion by experienced staff. After 1 week, antidiabetic regimen was changed to insulin glargine with an initial dose 40% to 50% of the previous total daily dose of premixed insulin. At the same time liraglutide was also started with an initial dose of 0.6 mg/day with subsequent up-titration to 1.2 mg/day after 1 week, if well tolerated. Repaglinide 1 to 2 mg 3 times per day were prescribed to reach the goal of postprandial glucose level < 180 mg/dL. Insulin glargine dose was regularly up-titrated at weekly interval according to fasting plasma glucose to reach goal of 90 to 130 mg/dL or reaching insulin dose of 50% of patient’s weight. After a total treatment duration of 12 weeks, another CGMS procedure were performed again The glycemic index, clinical cardiovascular risk profiles, safety issues (body weight and hypoglycemia), and GV indices from CGMS before and after 3 months treatment modification was evaluated.
Body mass index (BMI) was calculated as body weight (kg)/height (m2). Systolic blood pressure and diastolic blood pressure were measured in the right arm of seated individuals by using a standard mercury sphygmomanometer.
Liu J.S., Su S.C., Kuo F.C., Li P.F., Huang C.L., Ho L.J., Chen K.C., Liu Y.C., Lin C.P., Cheng A.C., Lee C.H., Lin F.H., Hung Y.J., Liu H.Y., Lu C.H, & Hsieh C.H. (2023). The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy. Medicine, 102(10), e33167.
Full text: Click here
Publication 2023
Alanine Transaminase Antidiabetics Aspartate Transaminase Body Weight Diagnosis Ethics Committees, Research Glucose Health Services, Outpatient Hypoglycemia Index, Body Mass Insulin Insulin Aspart Insulin Glargine Liraglutide Mercury Metformin NovoMix 30 Patients Plasma Pressure, Diastolic Protamines repaglinide Safety Sphygmomanometers Systolic Pressure Titrimetry Treatment Protocols
5
Assessing Mental Health and Substance Use
Social anxiety was assessed with the French version (Douillez et al. 2008 ) of the Fear of Negative Evaluation (FNE; Watson and Friend 1969 (link)). The FNE consists of 30 items rated as 1 = “true” or 0 = “false” (e.g., “I am afraid others will not approve of me”). Scores range from 0 to 30 with higher scores indicating higher levels of social anxiety.
Paranoia was assessed with the French version (Della Libera et al. 2021 (link)) of the Green et al. Paranoid Thoughts Scale, part B (GPTS-B; Green et al. 2008 (link)). The GPTS-B consists of 16 items (e.g., “People have intended me harm”). Participants rate the intensity of such thoughts during the last month on a 5-point scale ranging from 1 = “not at all” to 5 = “totally”. Scores range from 16 to 80 with higher scores indicating a higher level of paranoia.
Severity of depressive symptoms experienced during the last 7 days were assessed with the French version (Fuhrer and Rouillon 1989 (link)) of the Center for Epidemiologic Studies—Depression (CES-D; Radloff 1977 (link)). The CES-D consists of 20 items rated on a scale ranging from 0 = “never” to 3 = “frequently, all the time”. Scores range from 0 to 60 with higher scores indicating higher symptom severity. In addition, a score of 16 or above indicates the presence of depressive symptomatology.
Alcohol consumption was assessed with the French version (Gache et al. 2005 (link)) of the Alcohol Use Disorder Identification Test (AUDIT; Saunders et al. 1993 (link)). The AUDIT includes 10 multiple-choice items measuring alcohol consumption, alcohol dependence and alcohol-related problems. A score ranging from 0 to 40 is obtained by adding the score of each item. A score above 10 indicates an at-risk consumption (Fleming et al. 1991 (link)).
Nicotine consumption was assessed with a series of questions where participants indicated whether they were smokers, former smokers or non-smokers. The average number of cigarettes smoked par day, the frequency and duration of their addiction were asked for smokers and former smokers. Former smokers were also asked to indicate when they stopped smoking, the number of years they smoked, and the average number of cigarettes they smoked each day. These questions allowed to identify the smoking pattern of the current and former smokers.
Della Libera C., Simon J., Larøi F., Quertemont E, & Wagener A. (2023). Using 360-degree immersive videos to assess multiple transdiagnostic symptoms: A study focusing on fear of negative evaluation, paranoid thoughts, negative automatic thoughts, and craving. Virtual Reality.
Publication 2023
Addictive Behavior Alanine Transaminase Alcoholic Intoxication, Chronic Alcohol Problem Alcohol Use Disorder Depressive Symptoms Fear Friend Nicotine Non-Smokers Paranoia Social Anxiety Thinking

Top products related to «Alanine Transaminase»

1
Au5800 by Beckman Coulter
Sourced in United States, Japan, Germany, United Kingdom, China, Italy, Canada
The AU5800 is a chemistry analyzer designed for high-throughput clinical laboratory testing. It features advanced optics and automation to provide reliable and efficient sample processing. The core function of the AU5800 is to perform a variety of clinical chemistry tests, including immunoassays, on patient samples.
2
Enzychrom alanine transaminase assay kit by BioAssay Systems
Sourced in United States
The EnzyChrom™ Alanine Transaminase Assay Kit is a colorimetric assay designed to quantitatively measure the activity of the enzyme alanine transaminase (ALT) in biological samples. The kit provides a simple, direct, and high-throughput procedure to determine ALT levels.
3
Alanine transaminase colorimetric activity assay kit by Cayman Chemical
Sourced in United States
The Alanine Transaminase Colorimetric Activity Assay Kit is a laboratory product designed to measure the activity of the enzyme alanine transaminase (ALT) in biological samples. The kit utilizes a colorimetric method to quantify ALT levels, providing a reliable and efficient tool for researchers and clinical laboratories.
4
Cobas 8000 by Roche
Sourced in Switzerland, Germany, United States, Japan, France, Italy, China, United Kingdom, Sweden
The Cobas 8000 is a modular, automated in-vitro diagnostic system designed for high-throughput clinical chemistry and immunochemistry testing. It is used to perform a wide range of laboratory tests, including those for chemistry, immunoassay, and electrolyte analysis. The Cobas 8000 is capable of processing a large volume of samples efficiently and accurately.
5
Au5400 by Olympus
Sourced in Japan, United States, China
The AU5400 is a clinical chemistry analyzer designed for high-volume routine testing in medical laboratories. It utilizes a comprehensive menu of tests to provide accurate and reliable results for a wide range of analytes. The AU5400 is equipped with a high-speed reaction carousel and advanced analytical technology to ensure efficient and consistent performance.
6
Vettest chemistry analyzer by IDEXX
Sourced in United States
The VetTest Chemistry Analyzer is a laboratory instrument designed to perform a variety of clinical chemistry tests on small animal samples. It is capable of analyzing a range of analytes, including enzymes, electrolytes, and other biochemical markers, to aid in the diagnosis and monitoring of various medical conditions in veterinary patients.
7
Alanine transaminase activity assay kit by Abcam
Sourced in United States, United Kingdom
The Alanine Transaminase Activity Assay Kit is a colorimetric assay that quantifies the activity of the enzyme alanine transaminase (ALT) in biological samples. The kit provides a simple, direct, and high-throughput method for measuring ALT activity.
8
Au480 by Beckman Coulter
Sourced in United States, Germany, Japan, United Kingdom, Australia
The AU480 is an automated chemistry analyzer from Beckman Coulter designed for routine clinical chemistry testing. It utilizes spectrophotometric technology to perform a variety of assays on biological samples.
9
Au680 by Beckman Coulter
Sourced in United States, Germany, Japan, United Kingdom
The AU680 is an automated clinical chemistry analyzer designed for high-throughput clinical laboratory testing. It features a modular design, advanced analytical technologies, and comprehensive test menu capabilities to provide efficient and reliable results.
10
Mak052 by Merck Group
Sourced in United States
MAK052 is a laboratory equipment item manufactured by Merck Group. It is designed for specific scientific applications, but a detailed description cannot be provided while maintaining an unbiased and factual approach. Further information about the core function and intended use of this product is not available.

More about "Alanine Transaminase"

Alanine Transaminase (ALT) is a crucial enzyme found in the liver and other tissues, playing a vital role in amino acid metabolism.
It catalyzes the reversible transfer of an amino group from alanine to α-ketoglutarate, producing pyruvate and glutamate.
Elevated ALT levels can indicate liver injury or disease, making it an important biomarker for monitoring and diagnosing conditions like hepatitis, cirrhosis, and non-alcoholic fatty liver disease.
Accurate and reproducible ALT analysis is essential for clinical decision-making and research.
PubCompare.ai's AI-driven protocols can enhance the reproducibility and accuracy of ALT analysis by leveraging intelligent comparisons to identify the best protocols and products from literature, pre-prints, and patents.
Optimize your ALT research with PubCompare.ai's seamless integration of scientific data.
ALT, also known as SGPT (serum glutamic-pyruvic transaminase), is commonly measured using assays like the AU5800, EnzyChrom™ Alanine Transaminase Assay Kit, and the Alanine Transaminase Colorimetric Activity Assay Kit.
These tools provide accurate and reliable ALT measurements, which are crucial for monitoring liver health and diagnosing conditions like hepatitis and cirrhosis.
The Cobas 8000, AU5400, and VetTest Chemistry Analyzer are also commonly used for ALT analysis in clinical and research settings.
The Alanine Transaminase Activity Assay Kit, AU480, and AU680 are additional tools that can be used to measure ALT levels with high precision.
These assays leverage colorimetric or fluorometric methods to quantify ALT activity, offering a reliable way to assess liver function and detect liver injuries or diseases.
The MAK052 Alanine Transaminase Assay Kit is another option for researchers and clinicians looking to accurately measure ALT levels in various biological samples.